Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CAVA Group Inc (CAVA) vs TG Therapeutics Inc (TGTX) Price & Performance

CAVA Group IncTrade
TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

CAVA Group Inc vs TG Therapeutics Inc — how do they compare? CAVA Group Inc trades at $69.55 (market cap $7.08B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: CAVA Group Inc and TG Therapeutics Inc are close in size by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, CAVA Group Inc nearer its low. Which is the better fit depends on your goals.

CAVATGTX
Market Cap
$7.08B$7.64B
Sector
Consumer CyclicalHealth
52-Week High
$97.39$59.06
52-Week Low
$43.59$26.94
Enterprise Value
$7.23B$7.84B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CAVA Group Inc

CAVA Group (CAVA) is trading at $69.47, up 12.81% following strong Q2 2026 earnings that beat estimates with $0.19 EPS and 31.3% revenue growth. The stock shows bearish technical signals despite recent momentum, with key resistance at $62-64. Fundamentally, CAVA maintains robust revenue expansion and profitability with 24.69% gross margins, though valuation multiples remain elevated at P/E of 108.59.

The outlook remains positive given analyst consensus of 19 buys and $89.75 price target, representing 29% upside potential. Key risks include high valuation sensitivity, competitive pressures in fast-casual dining, and execution challenges in restaurant expansion. Recent same-store sales growth of 9% supports continued momentum if operational excellence persists.

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CAVA Group Inc

CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.

Read more on CAVA

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX